Therakind Sponsors DDL 2023
Therakind is pleased to announce its sponsorship at Drug Delivery to the Lung (DDL) 2023 taking place in Edinburgh between 6th and 8th December. DDL is a renowned respiratory drug delivery conference that attracts over a thousand participants from around the world working in academia and industry.
We will be presenting our DriDose dry powder nasal technology which includes multi-dose, unit dose and preclinical devices, and sharing our expertise in innovative drug delivery. We are introducing new formats of the DriDose technology for the first time at DDL 2023. All devices can be tailored to meet the needs of our partner and the drug candidate.
We are excited to exhibit our devices at DDL 2023 and look forward to exchanging knowledge with professionals in the field. We will be at booth #196- visit us to discuss nasal formulation development and drug delivery.
For those interested in partnering DriDose® with Therakind, please contact us on bd@therakind.com
Therakind Contact:
Therakind +44 (0) 208 346 6035
About Therakind Limited
Therakind is a specialty pharmaceutical company focused on developing niche medicines in difficult-to-treat markets including paediatric and geriatric patient groups.
Our proprietary pipeline is focused on improving medicine adherence through more patient-friendly dosing options and we have a strong track record in the research and development of innovative medicines and drug delivery systems designed specifically to take into account the pharmacodynamics and pharmacokinetics of difficult-to-treat patient groups. DriDose®, our intranasal device for the delivery of a dry powder drug formulation is available for co-development. We have also developed a device that is adapted for nasal delivery in a preclinical setting.
To find out more, please visit www.therakind.com